Malignant neoplasm of soft tissue
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Exposure of sarcoma and PDX ovarian carcinoma cells to [pazopanib + entinostat] caused a prolonged activation of ERBB1 and transient/prolonged activations of ERBB2, c-KIT, and c-MET, in a cell-specific fashion.
|
31380285 |
2019 |
Malignant neoplasm of soft tissue
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Seven samples from six patients were eligible for molecular testing of epidermal growth factor receptor (EGFR), V-Ki-ras2 Kirsten rat sarcoma viral oncogene homologue (KRAS), v-Raf murine sarcoma viral oncogene homologue B1 (BRAF) and human epidermal growth factor receptor 2 (HER2) mutations using quantitative polymerase chain reaction (PCR) high-resolution melting curve analysis and Sanger sequencing after DNA extraction from the cell pellets of the CSF.
|
29306909 |
2018 |
Malignant neoplasm of soft tissue
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Sixty-nine HER2 kinase domain mutations were identified in tumors from 68 patients (approximately 1% of all cases, ranging from absent in sarcomas to 4% in urothelial cancers), which included previously published activating mutations and 13 novel mutations.
|
26320869 |
2015 |
Malignant neoplasm of soft tissue
|
0.100 |
Biomarker
|
group |
BEFREE |
We conducted a phase I/II clinical study in which patients with recurrent/refractory human epidermal growth factor receptor 2 (HER2) -positive sarcoma received escalating doses (1 × 10(4)/m(2) to 1 × 10(8)/m(2)) of T cells expressing an HER2-specific chimeric antigen receptor with a CD28.ζ signaling domain (HER2-CAR T cells).
|
25800760 |
2015 |
Malignant neoplasm of soft tissue
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The current results suggest absence of ERBB-2 overexpression in uterine leiomyosarcoma, uterine adenosarcoma, and endometrial stromal sarcoma, whereas the ERBB-2 gene might have a biologic role in uterine carcinosarcoma and undifferentiated uterine sarcomas.
|
15581967 |
2004 |
Malignant neoplasm of soft tissue
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Four of 13 sarcomas (31%) demonstrated HER2/neu mRNA levels above the mean value, whereas 3 tumors (23%) displayed HER2/neu protein overexpression.
|
12874758 |
2003 |
Malignant neoplasm of soft tissue
|
0.100 |
Biomarker
|
group |
BEFREE |
In this study, we demonstrate that long-term administration of soluble alpha-GalCer, spanning the time of tumor initiation, inhibits primary tumor formation in three different models: methylcholanthrene-induced sarcomas, mammary carcinomas in Her-2/neu transgenic mice, and spontaneous sarcomas in p53-/- mice.
|
12867593 |
2003 |
Malignant neoplasm of soft tissue
|
0.100 |
AlteredExpression
|
group |
BEFREE |
It has been reported that the c-erbB-2 protooncogene is frequently amplified and overexpressed in many types of cancers, except sarcomas and hematological malignancies.
|
8630943 |
1996 |
Malignant neoplasm of soft tissue
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Increased expression of EGF-R and c-erbB-2 was identified in 21 of 43 (49%) and 35 of 94 (37%) sarcomas, respectively.
|
8098266 |
1993 |
Malignant neoplasm of soft tissue
|
0.100 |
Biomarker
|
group |
BEFREE |
Overexpression of the c-erbB-2 oncogene in sarcomas and small round-cell tumors of childhood. An immunohistochemical investigation.
|
1358045 |
1992 |
Malignant neoplasm of soft tissue
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Amplification of c-erbB-2 was at least three times more frequent in breast cancer than in most other types of carcinoma, and was not found in sarcomas or hematological malignancies.
|
3664511 |
1987 |